http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 02 Mar 2026 08:01:45 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html <p>Pulmatrix Inc. (NASDAQ: PULM) announced that Cullgen Inc. terminated their merger agreement on February 28, 2026, ending a planned transaction that had been pending regulatory approval in China.</p><p>The biopharmaceutical company said Cullgen had been seeking approval from the China Securities Regulatory Commission for the merger. The companies had originally entered into the merger agreement on November 13, 2024, with an amendment in April 2025.</p><p>Pulmatrix stockholders had approved the merger at a special meeting on June 16, 2025. The transaction required approval from Chinese regulators, which had not been obtained before Cullgen's termination notice.</p><p>In December 2025, both companies had agreed to http://www.streetinsider.com/Corporate+News/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html Mon, 02 Mar 2026 08:01:45 -0500 PULM http://www.streetinsider.com/Mergers+and+Acquisitions/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html <p>Pulmatrix Inc. (NASDAQ: PULM) announced that Cullgen Inc. terminated their merger agreement on February 28, 2026, ending a planned transaction that had been pending regulatory approval in China.</p><p>The biopharmaceutical company said Cullgen had been seeking approval from the China Securities Regulatory Commission for the merger. The companies had originally entered into the merger agreement on November 13, 2024, with an amendment in April 2025.</p><p>Pulmatrix stockholders had approved the merger at a special meeting on June 16, 2025. The transaction required approval from Chinese regulators, which had not been obtained before Cullgen's termination notice.</p><p>In December 2025, both companies had agreed to http://www.streetinsider.com/Mergers+and+Acquisitions/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html Mon, 02 Mar 2026 08:01:45 -0500 PULM http://www.streetinsider.com/Hot+Corp.+News/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html <p>Pulmatrix Inc. (NASDAQ: PULM) announced that Cullgen Inc. terminated their merger agreement on February 28, 2026, ending a planned transaction that had been pending regulatory approval in China.</p><p>The biopharmaceutical company said Cullgen had been seeking approval from the China Securities Regulatory Commission for the merger. The companies had originally entered into the merger agreement on November 13, 2024, with an amendment in April 2025.</p><p>Pulmatrix stockholders had approved the merger at a special meeting on June 16, 2025. The transaction required approval from Chinese regulators, which had not been obtained before Cullgen's termination notice.</p><p>In December 2025, both companies had agreed to http://www.streetinsider.com/Hot+Corp.+News/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html Mon, 02 Mar 2026 08:01:45 -0500 PULM http://www.streetinsider.com/Hot+M+and+A/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html <p>Pulmatrix Inc. (NASDAQ: PULM) announced that Cullgen Inc. terminated their merger agreement on February 28, 2026, ending a planned transaction that had been pending regulatory approval in China.</p><p>The biopharmaceutical company said Cullgen had been seeking approval from the China Securities Regulatory Commission for the merger. The companies had originally entered into the merger agreement on November 13, 2024, with an amendment in April 2025.</p><p>Pulmatrix stockholders had approved the merger at a special meeting on June 16, 2025. The transaction required approval from Chinese regulators, which had not been obtained before Cullgen's termination notice.</p><p>In December 2025, both companies had agreed to http://www.streetinsider.com/Hot+M+and+A/Pulmatrix+ends+merger+with+Cullgen%2C+seeks+new+deal/26087332.html Mon, 02 Mar 2026 08:01:45 -0500 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+28/26087361.html si-local-file:///var/storage/secattach/20260302/26087361.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+28/26087361.html Mon, 02 Mar 2026 08:01:00 -0500 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+28/26087361.html si-local-file:///var/storage/secattach/20260302/26087361.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+28/26087361.html Mon, 02 Mar 2026 08:01:00 -0500 O.16904700 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html <div class="xn-content"> <p class="prntac"><i>Cullgen had been seeking approval for a merger with <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> from the <span value="ACORN:2924680090" idsrc="xmltag.org" >China Securities Regulatory Commission</span> and on <chron>February 28, 2026</chron>, notified <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> that Cullgen was terminating the Merger Agreement </i></p><p class="prntac"><i>- <span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span> advances existing discussions on alternative merger opportunities - </i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>March 2, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4630209-1&amp;h=3918240064&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Termination+of+Prior+Planned+Merger+and+Continues+Pursuit+of+Alternative+Merger+Opportunities/26087297.html Mon, 02 Mar 2026 08:00:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Dec+31/26065035.html si-local-file:///var/storage/secattach/20260226/26065035.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Dec+31/26065035.html Thu, 26 Feb 2026 08:21:00 -0500 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Dec+31/26065035.html si-local-file:///var/storage/secattach/20260226/26065035.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Dec+31/26065035.html Thu, 26 Feb 2026 08:21:00 -0500 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+26/26064909.html si-local-file:///var/storage/secattach/20260226/26064909.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+26/26064909.html Thu, 26 Feb 2026 08:06:00 -0500 O.16904700 PULM http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+26/26064909.html si-local-file:///var/storage/secattach/20260226/26064909.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Pulmatrix%2C+Inc.+++++++++++For%3A+Feb+26/26064909.html Thu, 26 Feb 2026 08:06:00 -0500 O.16904700 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html <div class="xn-content"> <p class="prntac"><i>Plans to License or Monetize our Migraine and Inhalation Assets Continue</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628025-1&amp;h=3847546253&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html Thu, 26 Feb 2026 08:05:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html <div class="xn-content"> <p class="prntac"><i>Plans to License or Monetize our Migraine and Inhalation Assets Continue</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628025-1&amp;h=3847546253&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html Thu, 26 Feb 2026 08:05:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html <div class="xn-content"> <p class="prntac"><i>Plans to License or Monetize our Migraine and Inhalation Assets Continue</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628025-1&amp;h=3847546253&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html Thu, 26 Feb 2026 08:05:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html <div class="xn-content"> <p class="prntac"><i>Plans to License or Monetize our Migraine and Inhalation Assets Continue</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628025-1&amp;h=3847546253&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html Thu, 26 Feb 2026 08:05:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html <div class="xn-content"> <p class="prntac"><i>Plans to License or Monetize our Migraine and Inhalation Assets Continue</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628025-1&amp;h=3847546253&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html Thu, 26 Feb 2026 08:05:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html <div class="xn-content"> <p class="prntac"><i>Plans to License or Monetize our Migraine and Inhalation Assets Continue</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628025-1&amp;h=3847546253&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html Thu, 26 Feb 2026 08:05:00 -0500 A.29246800 O.16904700 O.50899713 PULM http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html <div class="xn-content"> <p class="prntac"><i>Plans to License or Monetize our Migraine and Inhalation Assets Continue</i></p><p><span class="legendSpanClass"><location value="LU/us.ma.fraham" idsrc="xmltag.org" >FRAMINGHAM, Mass.</location></span>, <span class="legendSpanClass"><chron>Feb. 26, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4628025-1&amp;h=3847546253&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2779419-1%26h%3D2224270520%26u%3Dhttp%253A%252F%252Fwww.pulmatrix.com%252F%26a%3DPulmatrix%252C%2BInc.&amp;a=Pulmatrix%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix, Inc.</span></a> ("<span value="NASDAQ-NMS:PULM" idsrc="xmltag.org" >Pulmatrix</span>" or the "Company") (Nasdaq: PULM), a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented iSPERSE™ technology, today announced year-end and fourth quarter financial results for 2025 and provided a corporate update.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/PRNewswire/Pulmatrix+Announces+Year-End+and+Fourth+Quarter+2025+Financial+Results/26064902.html Thu, 26 Feb 2026 08:05:00 -0500 A.29246800 O.16904700 O.50899713 PULM